Impact of metformin on advanced pancreatic cancer survival: Too little, too late?

Abstract

Metformin offers no survival advantage in patients with metastatic pancreatic cancer. Despite promising experimental evidence suggesting an antitumor effect of metformin, its impact on the survival of advanced pancreatic cancer is likely very limited. Future studies may need to consider its role in early-stage pancreatic cancer. Clin Cancer Res; 22(5); 1031-3.